Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Hui YangCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-0043-8793
Tereza ClarenceCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-0099-2797
Madeline R ScottDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-2059-2256
Xinyi WangCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-8003-4216
N M PrashantCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-3548-5637
Milos PjanicCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9746-8838
Sanan VenkateshCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-3094-2731
Aram HongCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0000-6083-1998
Clara CaseyCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0002-9430-3557
Sarah R MurphyCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0005-1296-6325
Alexander Kawah YuCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0006-3253-0745
Zhiping ShaoCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0006-4889-6637
Marcela AlviaCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9706-1376
Stathis ArgyriouCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0008-0713-6599
PsychAD Consortium
Nadejda M TsankovaFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0009-0007-0943-3872
Pavan K AuluckHuman Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda, MD, USA.ORCID 0000-0003-4799-7904
Stefano MarencoHuman Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda, MD, USA.ORCID 0000-0002-2488-2365
Vahram HaroutunianFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-5860-2512
Georgios VoloudakisCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-5729-632X
Jaroslav BendlCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9989-2720
Colleen A McClungDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0003-4719-6197
Donghoon LeeCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-0453-6059
John F FullardCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-9874-2907
Gabriel E HoffmanCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-0957-0224
Kiran GirdharCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-5622-042X
Panos RoussosCenter for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-4640-6239
Funding
Procurement and Characterization of Postmortem Brain TissueZICMH002903 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MARENCO, STEFANO · 2009 to 2025
$56.0M
Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer DiseaseR01AG067025 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FINKBEINER, STEVEN M, HAROUTUNIAN, VAHRAM · 2019 to 2023
$11.8M
TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2020 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2025, CLOSING OF THE PERIOD OF AVAILABI75N95019C00049 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM · 2019 to 2025
$11.8M
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer DiseaseR01AG065582 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, ROUSSOS, PANAGIOTIS · 2020 to 2024
$9.9M
The adaptive-innate immune interactome across multiple tissues in Alzheimer's diseaseR01AG082185 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI VAHRAM HAROUTUNIAN, Donghoon Lee · 2023 to 2026
The dorsolateral prefrontal cortex (DLPFC) underpins higher cognitive functions and is highly susceptible to age-related decline. However, a comprehensive, lifespan-resolved map of its cellular and molecular programs has been lacking. Here, we constructed the first single-nucleus transcriptomic atlas of the human DLPFC, spanning the full lifespan, profiling over 1.3 million nuclei from 284 postmortem samples ranging in age from 0-97 years. This unprecedented resource reveals three distinct transcriptomic phases: dynamic developmental remodeling, midlife stability, and late-life molecular reactivation. Non-linear modeling of age trends uncovers ten distinct trajectories, including a neuronal resilience program peaking in early adolescence and glial aging programs marked by immune activation in late adulthood. Pseudotime analyses reconstruct lineage maturation from fetal progenitors to aged states, identifying gene modules linked to neurodevelopmental and neurodegenerative disease risk. Spatial transcriptomics confirm these dynamic programs, mapping excitatory neuron modules to specific cortical layers and glial signatures to distinct gray-white matter domains. Notably, we identify circadian reprogramming in late adulthood, with loss of neuronal core clock rhythmicity and emergence of stress-adaptive glial rhythms. Together, this study provides the first anatomically resolved, cell-type-specific, and lifespan-wide reference for the human DLPFC, establishing a foundational resource for understanding brain development, aging, and disease vulnerability.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A lifespan transcriptomic atlas of the human prefrontal cortex at single-cell resolution. · full record | OpenQuestion